PerspectiveViewpoint: COVID-19

Rapid COVID-19 vaccine development

See allHide authors and affiliations

Science  29 May 2020:
Vol. 368, Issue 6494, pp. 945-946
DOI: 10.1126/science.abb8923

Figures

  • Potential risks associated with vaccine development for COVID-19

    Antibodies that bind virus without neutralizing infectivity can cause disease through increased viral replication or formation of immune complexes that deposit in tissue and activate complement pathways associated with inflammation. T helper 2 cell (TH2)–biased responses have also been associated with ineffective vaccines that lead to enhanced disease after subsequent infection. Antibody-dependent enhancement (ADE) of viral replication has occurred in viruses with innate macrophage tropism. Virus-antibody immune complexes and TH2-biased responses can both occur in vaccine-associated enhanced respiratory disease (VAERD).

Stay Connected to Science

Navigate This Article